Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2023-03-17 Proxy Solicitation & In…
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement or related materials filed with the SEC. The text indicates it is a 'Definitive Additional Materials' filing related to a Proxy Statement under Section 14(a) of the Securities Exchange Act of 1934. This type of document is used to provide additional information or amendments to the Proxy Statement, which is used to solicit shareholder votes. According to the filing definitions, Proxy Solicitation & Information Statement (PSI) covers materials sent to shareholders to provide information and request votes for meetings. The document length is short (1222 characters) and it is clearly a proxy-related filing, not the full Proxy Statement itself but additional materials related to it. Therefore, the best classification is PSI with high confidence.
2023-03-17 English
DEF 14A
Proxy Solicitation & Information Statement
2023-03-17 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which relates to the departure or appointment of directors or certain officers. Specifically, it details a non-competition and non-solicitation agreement with an officer, Daniel Skovronsky, including payment terms. There is no financial data or earnings information, nor is it an annual or quarterly report. The document is not a proxy, voting result, or legal proceeding. It clearly announces a management change-related agreement, fitting the category of Board/Management Information (MANG). The document length is 4312 characters, which is short but contains substantive information about management changes, not just an announcement of a report. Therefore, the correct classification is MANG with high confidence.
2023-03-17 English
FORM 4
Director's Dealing
2023-03-13 English
FORM 4
Director's Dealing
2023-03-02 English
FORM 4
Director's Dealing
2023-03-02 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.